Fig. 1: TET3 promotes HGP.

a and b qPCR and immunoblotting (IB) of TET3, PCK1, and G6PC at 72 h following infection with Ad-GFP or Ad-TET3 in H19 KO hepatocytes. n = 3. Molecular sizes of the proteins in kDa are marked on the right. c Glucose production by H19 KO hepatocytes at 72 h following infection with Ad-GFP or Ad-TET3. n = 3. d and e qPCR and IB of TET3, PCK1, and G6PC at 48 h of glucagon stimulation following infection with AAV-scr or AAV-siTET3 for 24 h in primary hepatocytes. n = 3. f Glucose production by primary hepatocytes at 48 h of glucagon stimulation following infection with AAV-scr or AAV-siTET3 for 24 h. n = 3. g and h qPCR and IB of TET3, PCK1, and G6PC from liver tissues isolated from H19 KO mice injected via tail vein with Ad-GFP or Ad-TET3. n = 4–6. Liver tissues were collected from ad libitum-fed mice on day 10 post infection. i Blood glucose and insulin levels of H19 KO mice treated as in g. n = 6. j Fasting blood glucose and insulin levels of mice 10 days after infection with AAV-scr or AAV-siTET3. n = 5–6. k PTT in mice treated as in j. n = 5–6, two-way ANOVA with Sidak post-test. l IB of TET3, PEPCK, and G6PC proteins from liver tissues isolated from mice treated as in j. n = 4. Data a–f are representative of at least two independent experiments; data g–l are representative of two independent experiments. Two-tailed Student’s t tests (or as otherwise indicated) were used to compare means between groups. All data are presented as mean ± SEM. *p < 0.05, **p < 0.01. Source data are provided as a Source Data File.